India Glycine: Prelim Results of CVD Admin Review
The Commerce Department has published the preliminary results of its countervailing duty administrative review on glycine from India (C-533-884). The agency calculated a CVD rate of 9.41% for the two companies remaining under review, Kumar Industries, India, and Bajaj Healthcare Limited. Any changes to the cash deposit rate would take effect on the publication date of the final results of this review in the Federal Register. In the final results, Commerce also will set assessment rates for subject merchandise from Kumar and Bajaj entered Jan. 1, 2023, through Dec. 31, 2023.
Sign up for a free preview to unlock the rest of this article
If your job depends on informed compliance, you need International Trade Today. Delivered every business day and available any time online, only International Trade Today helps you stay current on the increasingly complex international trade regulatory environment.
Commerce also said that it is rescinding this review for 17 companies that had their requests for review withdrawn. See Appendix II of the notice for a full list. CBP will continue to collect cash deposits of estimated CVD at the most recent company-specific or all-others rate applicable to the companies on the list, as appropriate. Any subject merchandise entered under their CVD case numbers would be liquidated at a rate equal to the cash deposit of estimated CVD required at the time of entry, or withdrawal from warehouse, for consumption, during calendar year 2023.
Commerce will order liquidation “as entered” at the cash deposit rate in effect at the time of entry for subject merchandise entered Jan. 1, 2023, through Dec. 31, 2023, that was exported by companies that are not under review (currently, all except Kumar and Bajaj).
(The period of review is 01/01/23 - 12/31/23. See the notice for additional information, including the scope of the order, potential cash deposit and assessment instructions, etc.).